Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AMG 333 in Healthy and Migraine Subjects
NCT02132429Phase 1Terminated
- Sponsor
- Amgen
- Start
- May 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in migraine comparing AMG 333 with Placebo (2 arms). Primary endpoint: Treatment-emergent Adverse Events up to 29 Days. Started May 2014; status: terminated.
02
Drugs
AMG 333
03
Conditions
migraine
Beyond the preview
Go deeper on NCT02132429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02132429.